First‐line R‐CVP versus R‐CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4

R‐CVP (cyclophosphamide, vincristine, prednisone) and R‐CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone + rituximab) are immunochemotherapy regimens frequently used for remission induction of indolent non‐Hodgkin lymphomas (iNHLs). Rituximab maintenance (RM) significantly improves progr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Haematol
Autors principals: Walewski, Jan, Paszkiewicz‐Kozik, Ewa, Michalski, Wojciech, Rymkiewicz, Grzegorz, Szpila, Tomasz, Butrym, Aleksandra, Giza, Agnieszka, Zaucha, Jan M., Kalinka‐Warzocha, Ewa, Wieczorkiewicz, Agata, Zimowska‐Curyło, Dagmara, Knopińska‐Posłuszny, Wanda, Tyczyńska, Agata, Romejko‐Jarosińska, Joanna, Dąbrowska‐Iwanicka, Anna, Gruszecka, Beata, Jamrozek‐Jedlińska, Maria, Borawska, Anna, Hołda, Waldemar, Porowska, Agnieszka, Romanowicz, Agnieszka, Hellmann, Andrzej, Stella‐Hołowiecka, Beata, Deptała, Andrzej, Jurczak, Wojciech
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Haematological Malignancy – Clinical
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7154735/
https://ncbi.nlm.nih.gov/pubmed/31792945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16264
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars